Analysis of the status and influencing factors of metabolism-related fatty liver disease among employees of different genders in enterprises in Wuhu City

Abstract

Abstract: Objective To analyze the status quo of metabolism-related fatty liver disease（MAFLD） in employees of different genders in Wuhu City,identify its risk factors,and explore the predictive value of each index. Methods A total of 29 684 patients from seven large enterprises who underwent occupational health examination in the health management center of a hospital in Wuhu City from June to November 2022 were selected as the study objects. MAFLD was evaluated by abdominal ultrasonography and physical examination,and was divided into non-MAFLD group（19 812 cases） and MAFLD group（9 872 cases）. The prevalence and characteristics of MAFLD in different genders were analyzed. Multivariate logistic regression analysis was used to explore the influencing factors of MAFLD population with different genders. The predictive value of each indicator was analyzed by receiver operating characteristic（ROC） curve,and the area under ROC curve（AUC）,sensitivity and specificity were calculated. Results The average age of 29 684 subjects was （45.18±13.57）years,and the total prevalence was 33.26%.There were 16 171 males（54.50%）and 7 648 males with MAFLD（prevalence 47.29%）.There were 13 513 females（45.50%）and 2 224 females with MAFLD,with a prevalence rate of 16.46%.There was a statistically significance difference in the prevalence of MAFLD between different genders（χ²=3 153.570,P<0.01）. Multivariate logistic regression analysis showed that body mass,triglycerides,fasting blood glucose,low density lipoprotein,total cholesterol,high density lipoprotein,and aspartate/alanine aminotransferase were the common influencing factors for MAFLD patients among enterprise employees（all P<0.05）. Among them,diastolic blood pressure,total bilirubin,aspartate and uric acid were independent influencing factors of MAFLD in male physical examination subjects（all P<0.05）. Age,total protein and albumin were the independent influencing factors of female MAFLD（all P<0.05）. ROC curve analysis results showed that body mass,triacylglycerol and body mass combined triacylglycerol had the highest predictive value for MAFLD patients. Conclusion The factors affecting the occurrence of MAFLD in male and female employees in Wuhu City were slightly different,but body weight,triglyceride,fasting blood glucose,low density lipoprotein,total cholesterol,high density lipoprotein,and aspartate/alanine aminotransferase were both influencing factors. Anong people of different genders,body mass combined with triglyceride has high predictive value and can predict the occurrence of MAFLD in Wuhu employees.

Key words: Metabolism-related fatty liver, Enterprise employee, Gender factors, Influencing factors

CLC Number:

R181.3

WU Yan, ZHANG Xiancui, XU Yan, WANG Jiangbo, LI Lei, WANG Zhen. Analysis of the status and influencing factors of metabolism-related fatty liver disease among employees of different genders in enterprises in Wuhu City. [J]OCCUPATION AND HEALTH, 2025, 41(14): 1924-1930.

References

[1] SHIHA G,KORENJAK M,ESKRIDG W,et al.Redefining fatty liver disease:an international patient perspective[J].Lancet Gastroenterol Hepatol,2021,6(1):73-79.
[2] LIANG Y,Chen H,LIU Y,et al.Association of MAFLD with diabetes,chronic kidney disease,and cardiovascular disease:A 4.6-year cohort study in China[J]. J Clin Endocrinol Metab,2022,107(1):88-97.
[3] FAN J,LUO S,Ye Y,et al.Prevalence and risk factors of metabolic associated fatty liver disease in the contemporary South China population[J].Nutr Metab,2021,18(1):82.
[4] ESLAM M,SARIN S K,WONG V W,et al.The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic-associated fatty liver disease[J].Hepatol Int,2020,14(6):889-919.
[5] LEE H,LEE Y H,KIM S U,et al.Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk:A Nationwide Cohort Study[J].Clin Gastroenterol Hepatol,2021,19(10):2138-2147.
[6] HUANG Q,ZOU X,WEN X,et al.NAFLD or MAFLD:Which Has Closer Association With All-Cause and Cause-Specific Mortality[J]. Front Med,2021,8:693507.
[7] 中华医学会超声医学分会,中国研究型医院学会肿瘤介入专业委员会,国家卫生和健康委员会能力建设和继续教育中心超声医学专家委员会.肝病超声诊断指南[J].中华肝脏病杂志,2021,29(5):385-402.
[8] POPKIN B M,NG S W.The nutrition transition to a stage of high obesity and noncommunicable disease prevalence dominated by ultra-processed foods is not inevitable[J].Obes Rev,2022,23(1):e13366.
[9] CHIA A,ONG J,BUNDELE A,et al.Social entrepreneurship in obesity prevention:A scoping review[J].Obes Rev,2022,23(3):e13378.
[10] WELLS JC,SAWAYA AL,WIBAEK R,et al.The double burden of malnutrition:Aetiological pathways and consequences for health[J].Lancet,2020,395(10217):75-88.
[11] ZHOU J,ZHOU F,WANG W,et al.Epidemiological features of NAFLD from 1999 to 2018 in China[J]. Hepatology,2020,71(5):1851-1864.
[12] ESTES C,ANSTEE QM,ARIAS-LOSTE M T,et al.Modeling NAFLD disease burden in China,France,Germany,Italy,Japan,Spain,United Kingdom,and the United States for the period 2016-2030[J].J Hepatol,2018,69(4):896-904.
[13] LEI F,QIN J J,SONG X,et al.The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China[J].Front Endocrinol,2022,13:1007171.
[14] 王珊,张健,蒋晓忠,等.非肥胖人群的腰围轨迹与新发非酒精性脂肪肝的相关性[J].中华流行病学杂志,2020,41(6):824-828.
[15] SHAUNAK M,BYRNE CD,DAVIS N,et al.Non-alcoholic fatty liver disease and childhood obesity[J].Arch Dis Child,2021,106(1):3-8.
[16] LONARDO A,NASCIMBENI F,BALLESTRI S,et al.Sex differences in nonalcoholic fatty liver disease:state of the art and identification of research gaps[J].Hepatology,2019,70(4):1457-1469.
[17] LAZARUS J V,MARK H E,ANSTEE Q M,et al.Advancing the global public health agenda for NAFLD:A consensus statement[J].Nat Rev Gastroenterol Hepatol,2022,19(1):60-78.
[18] LAZARUS J V,MARK H E,COLOMBO M,et al.A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach[J].Aliment Pharmacol Ther,2022,55(2):234-243.
[19] ESLAM M,SARIN S K,WONG V W,et al.The Asian Pacific Association for the study of the Liver clinical practice guidelines for the diagnosis and management of metabolic-associated fatty liver disease[J].Hepatol Int,2020,14(6):889-919.
[20] VILAR-GOMEZ E,MARTINEZ-PEREZ Y,CALZADILLA-BERTOT L,et al.Weight Loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis[J].Gastroenterology,2015,149(2):367-378.
[21] ZHOU X D,CAI J,TARGHER G,et al.Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention[J].Cardiovasc Diabetol,2022,21(1):270.